CN107550867B - Antistatic tavermectin tartrate premix and preparation method thereof - Google Patents
Antistatic tavermectin tartrate premix and preparation method thereof Download PDFInfo
- Publication number
- CN107550867B CN107550867B CN201711008783.8A CN201711008783A CN107550867B CN 107550867 B CN107550867 B CN 107550867B CN 201711008783 A CN201711008783 A CN 201711008783A CN 107550867 B CN107550867 B CN 107550867B
- Authority
- CN
- China
- Prior art keywords
- agent
- preparation
- tartrate
- tavermectin
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses an antistatic tavermectin tartrate premix which comprises, by weight, 20-30% of tavermectin tartrate, 0.1-0.3% of an aromatic agent, 0.1-0.3% of a sweetening agent, 4-8% of a solvent (wetting agent), 5-12% of a stabilizer (dispersing agent), 0.1-0.3% of a metal ion chelating agent and 100% of a carrier. The invention also discloses a preparation method of the premix. The invention can solve the problems of bitter taste, electrostatic adsorption, dust emission, reaction with metal ions and the like of the tylosin tartrate, improve the bioavailability of the tylosin tartrate, and improve the production benefit and the economic benefit of a farm.
Description
Technical Field
The invention belongs to the technical field of veterinarians, and particularly relates to an antistatic tavermectin tartrate premix and a preparation method thereof.
Background
The mycoplasma hyopneumoniae is a chronic, contact and respiratory infectious disease caused by mycoplasma hyopneumoniae, is also called local swine epidemic pneumonia, is commonly called swine enzootic pneumonia in China, and has the main clinical symptoms of cough and asthma. The disease is widely distributed all over the world, and is one of important epidemic diseases which endanger the development of the pig industry, because sick pigs die directly or become cad pigs or die after secondary infection or grow and develop slowly, the growth rate and the feed utilization rate are reduced, and the serious economic loss is large.
Tylosin tartrate, namely acetylisovaleryltylosin tartrate, is a new generation of macrolide antibiotics, and is a macrolide antibiotic special for poultry and livestock, which is obtained by biological fermentation and semi-synthesis on the basis of tylosin, has antibacterial activity on a plurality of gram-positive bacteria and some gram-negative bacteria, including mycoplasma, vibrio, spirochete and the like, and has unique curative effects on mycoplasma gallisepticum, mycoplasma hyopneumoniae, swine dysentery and the like.
The common tylosin types on the market comprise soluble powder, conventional premix, injection, particles produced by a coating process and the like, the tylosin has the characteristic of bitter taste, and the soluble powder has the following defects: firstly, the palatability is poor, and the ingestion of animals is influenced; secondly, the soluble powder has small specific gravity and is easy to raise dust, thereby not only causing waste, but also influencing the health of operators; thirdly, the feed additive is easy to react with trace elements, electrolytes, acidifiers and the like in the feed in the using process, so that the drug effect is reduced; fourthly, the electrostatic adsorption effect is strong, and waste is easily caused in the production and use processes; fifthly, the tulathromycin is unstable and can be rapidly decomposed under the gastric acid condition, and the bioavailability is reduced. The injection increases labor force during use, and is easy to generate stress reaction during animal use, thereby influencing growth and development. Although the granular preparation produced by the coating process solves the palatability problem, the production time is long, the efficiency is low, the cost is high, the preparation is possibly uneven, and the use effect is influenced.
Therefore, the research and development of a preparation with good palatability, no dust emission, static resistance and ion resistance, low cost and good absorption and utilization rate and a preparation method thereof for improving the production benefit and the economic benefit of extensive farms are urgent.
In view of the above, the present inventors have specially studied an antistatic tavermectin tartrate premix and a preparation method thereof, and have generated the present application.
Disclosure of Invention
The invention aims to provide an antistatic tavermectin tartrate premix and a preparation method thereof, which are used for solving the problems of bitter taste, electrostatic adsorption, dust emission, reaction with metal ions and the like of tavermectin tartrate, improving the bioavailability and the production benefit and the economic benefit of a farm.
In order to achieve the above purpose, the solution of the invention is:
an antistatic tavermectin tartrate premix comprises, by weight, 20-30% of tavermectin tartrate, 0.1-0.3% of an aromatic agent, 0.1-0.3% of a sweetening agent, 0.1-0.3% of a metal ion chelating agent, 4-8% of a solvent (wetting agent), 5-12% of a stabilizer (dispersing agent) and 100% of a carrier.
The invention discloses a preparation method of an antistatic tavermectin tartrate premix, which comprises the following steps:
step 1: dissolving a metal ion chelating agent in water, dissolving a sweetening agent and an aromatic agent in a solvent (wetting agent), adding a stabilizing agent (dispersing agent), adding a metal ion chelating agent solution, and stirring to obtain a wetting agent A;
step 2: pouring the tylosin tartrate and the carrier into a groove-shaped mixer/stirring mixing device, adding half of the wetting agent A, covering the cover of the mixer, and mixing and stirring for 5 minutes;
and step 3: opening the cover of the mixer, adding the residual solution A, closing the cover, and continuing stirring for 10 minutes;
and 4, step 4: opening the cover, observing the properties of the materials, holding the materials by hand to form a cluster, wherein the cluster is free from dust emission and uniform in whole, and if the cluster is not uniform, continuing to close the cover and stirring the mixture until the cluster is uniform to obtain a material B;
and 5: sieving the material B with a 40-mesh sieve for 2 times to obtain a material C;
step 6: and pouring the material C into a mixer, and stirring and mixing for 15 minutes to obtain the material C.
The sweetener is at least one of steviosin and sorbitol.
The aromatic is at least one of orange essence, lemon essence and peppermint oil.
The solvent (wetting agent) is at least one of ethanol and propylene glycol
The stabilizer (dispersant) is at least one of polyethylene glycol 200, polyethylene glycol 400 and polyethylene glycol 600.
The metal ion chelating agent is at least one of sodium tripolyphosphate, citric acid and ethylene diamine tetraacetic acid.
The carrier is defatted rice bran with 80 meshes and the water content is below 5%.
The tylosin tartrate meets the high-efficiency, low-toxicity and low-residue raw material medicine of veterinary drug standards, can be combined with the 50S subunit of the nucleoprotein body of sensitive bacteria, and inhibits the synthesis and extension of a peptide chain by blocking transpeptidation and/or mRNA displacement, thereby influencing the synthesis of bacterial protein and playing the roles of bacteriostasis and sterilization. The tylosin tartrate has antibacterial activity on gram-positive bacteria such as staphylococcus, bacillus, streptococcus and clostridium and also has good inhibitory effect on mycoplasma.
The invention has the following advantages: the process adopts a granulation method, so that the final product is prepared into particles of about 40 meshes, no electrostatic action is generated, drying is not needed, the influence of temperature on effective components is avoided, and the dust flying condition in the use process is avoided; the sweetening agent, the aromatic agent and the like are added to play a role in flavoring and increasing the flavor, the palatability is improved, and the metal ion chelating agent can indirectly avoid the influence of metal ions in the feed on the tylosin tartrate.
Detailed Description
The present invention is further illustrated by, but is not limited to, the following examples:
example 1:
an antistatic tavermectin tartrate premix comprises, by weight, 20% of tavermectin tartrate, 0.1% of a sweetening agent, 0.1% of an aromatic agent, 4% of a solvent (wetting agent), 1.1% of a metal ion chelating agent solution, 6% of a stabilizer (dispersing agent) and 68.7% of a carrier.
The preparation method of the tylosin tartrate premix comprises the following specific steps: dissolving 1kg of metal ion chelating agent solution 10kg of water, 1kg of sweetening agent and 1kg of aromatic agent in 40L of solvent (wetting agent), adding 60L of stabilizing agent (dispersing agent), adding metal ion chelating agent solution, and stirring to obtain wetting agent A; pouring 200kg of tylosin tartrate and 687kg of carrier into a groove-shaped mixer/stirring and mixing device, adding half of the wetting agent A, covering the cover of the mixer, and mixing and stirring for 5 minutes; opening the cover of the mixer, adding the rest wetting agent A, closing the cover, and continuing stirring for 10 minutes; opening the cover, observing the material properties, holding the materials into a ball by a hand, and obtaining a material B, wherein the ball is free of dust raising and uniform in whole; sieving the material B with a 40-mesh sieve for 2 times to obtain a material C; and pouring the material C into a mixer, and stirring and mixing for 15 minutes to obtain the material C. The product obtained is smelled to have light fragrance, a small amount of the product and the tongue tip can be tasted to have slight sweet taste, the product obtained and the tylosin tartrate premix of the same kind are respectively arranged in two dry plastic bags and sealed, the plastic bag is rubbed back and forth by hands, and then the plastic bag is straightened and stood. The plastic bags are cut, the products are respectively poured out, the same type of tylosin tartrate premix drifts around in the pouring process, the dust emission phenomenon is obvious, the waste is serious, the invention is totally poured on a container, and the dust emission phenomenon is basically avoided.
Example 2:
an antistatic tavermectin tartrate premix comprises, by weight, 20% of tavermectin tartrate, 0.2% of a sweetening agent, 0.2% of an aromatic agent, 6% of a solvent (wetting agent), 2.2% of a metal ion chelating agent solution, 10% of a stabilizer (dispersing agent) and 61.4% of a carrier.
The preparation method of the tylosin tartrate premix comprises the following specific steps: dissolving 2kg of metal ion chelating agent solution 20kg of water, 2kg of sweetening agent and 2kg of aromatic agent in 60L of solvent (wetting agent), adding 100L of stabilizing agent (dispersing agent), adding metal ion chelating agent solution, and stirring to obtain wetting agent A; pouring 200kg of tylosin tartrate and 614kg of carrier into a groove-shaped mixer/stirring mixing device, adding half of the wetting agent A, covering the cover of the mixer, and mixing and stirring for 5 minutes; opening the cover of the mixer, adding the rest wetting agent A, closing the cover, and continuing stirring for 10 minutes; opening the cover, observing the material properties, holding the materials into a ball by a hand, and obtaining a material B, wherein the ball is free of dust raising and uniform in whole; sieving the material B with a 40-mesh sieve for 2 times to obtain a material C; and pouring the material C into a mixer, and stirring and mixing for 15 minutes to obtain the material C. The product obtained by smelling has comfortable fragrance, a small amount of the product and the tongue tip can be tasted sweet, the product obtained and the tylosin tartrate premix of the same kind are respectively arranged in two dry plastic bags and sealed, the plastic bags are rubbed back and forth by hands, and then the plastic bags are straightened and stood. The plastic bags are cut, the products are respectively poured out, the same type of tylosin tartrate premix drifts around in the pouring process, the dust emission phenomenon is obvious, the waste is serious, the invention is totally poured on a container, and the dust emission phenomenon is basically avoided. A piece of paper is laid on a black table top, 100g of the product is poured downwards from a position which is vertically 30cm away from the table top until the product is poured, no dust is basically generated when the product is observed by eyes, no dust stimulates the nasal cavity without wearing a mask, and no dust is basically generated on the black table top at the edge of the paper after 5 minutes. Similar products (without granulation) are operated by the same method, obvious dust raising can be seen, dust is dazzlingly felt when a mask is not worn, and a layer of dust is arranged on a black table top at the edge of paper after 5 minutes. Compared with other tylosin tartrate premix without granulation, the product has obvious advantage on dust resistance. The smaller the dust granularity is, the more obvious the phenomenon of being adsorbed in the place with static electricity can be, the granularity of the product is basically kept about 40 meshes, and the embarrassment of static adsorption and dust raising can be effectively avoided.
Example 3:
an antistatic tavermectin tartrate premix comprises, by weight, 20% of tavermectin tartrate, 0.3% of a sweetening agent, 0.3% of an aromatic agent, 8% of a solvent (wetting agent), 12% of a stabilizer (dispersing agent), 3.3% of a metal ion chelating agent solution and 56.1% of a carrier.
The preparation method of the tylosin tartrate premix comprises the following specific steps: dissolving 30kg of water in 3kg of metal ion chelating agent solution, dissolving 80L of solvent (wetting agent) in 3kg of sweetening agent and 3kg of aromatic agent, adding 120L of stabilizing agent (dispersing agent), adding metal ion chelating agent solution, and stirring to obtain wetting agent A; pouring 200kg of tylosin tartrate and 561kg of carrier into a groove-shaped mixer/stirring mixing device, adding half of wetting agent A, covering the cover of the mixer, and mixing and stirring for 5 minutes; opening the cover of the mixer, adding the rest wetting agent A, closing the cover, and continuing stirring for 10 minutes; opening the cover, observing the material properties, holding the materials into a ball by a hand, and obtaining a material B, wherein the ball is free of dust raising and uniform in whole; sieving the material B with a 40-mesh sieve for 2 times to obtain a material C; and pouring the material C into a mixer, and stirring and mixing for 15 minutes to obtain the material C. The product obtained by smelling has stronger fragrance, a small amount of the product and the tongue tip can taste heavier sweet taste, the product obtained and the tylosin tartrate premix of the same kind are respectively arranged in two dry plastic bags and sealed, the plastic bags are rubbed back and forth by hands, and then the plastic bags are straightened and stood. The plastic bags are cut, the products are respectively poured out, the same type of tylosin tartrate premix drifts around in the pouring process, the dust emission phenomenon is obvious, the waste is serious, the invention is totally poured on a container, and the dust emission phenomenon is basically avoided.
Example 4
The pig herd presents clinical symptoms: the antistatic tavermectin tartrate premix is used for treating and testing after dry cough, low frequency, gasp in mouth, increased respiration, listlessness, malaise, remarkable gasp during walking, abdominal respiration and dog sitting posture, autopsy of dead pigs, muscle-like lesion of lung spire, enlargement of lung portal and mediastinal lymph nodes, flesh-like lesion of pancreas, hypertrophic small bronchus, white mucus flowing out of tube walls, suspected mycoplasma pneumonia of pigs, and serum detection and diagnosis, so as to prove the clinical effect of the antistatic tavermectin tartrate premix. The method is characterized in that 25 sick pigs are randomly divided into 5 groups, each group comprises 5 pigs, the first group is fed with the product in the example 1, the second group is fed with the product in the example 2, the third group is fed with the product in the example 3, the fourth group is fed with the tylosin tartrate soluble powder purchased from the market, the fifth group is not fed with the medicine, after 3 days, the 1 st to 4 th groups of pigs are all well-transformed, no death occurs in the middle, the 1 st to 3 th groups of pigs have better symptoms than the 4 th group, the 2 nd group has the best effect, the fifth group has more symptoms, and one pig is dead, so that the tylosin tartrate premix has an obvious effect on treating swine mycoplasma pneumonia and is better than the tylosin tartrate soluble powder, and therefore, the economic loss of a farm can be reduced and the benefit can be improved by using the product.
Claims (4)
1. A preparation method of an antistatic tavermectin tartrate premix is characterized by comprising the following steps: according to weight percentage, the components of the composition are 20 to 30 percent of tylosin tartrate, 0.1 to 0.3 percent of aromatic, 0.1 to 0.3 percent of sweetening agent, 4 to 8 percent of solvent, 5 to 12 percent of stabilizing agent, 0.1 to 0.3 percent of metal ion chelating agent and 100 percent of carrier;
the solvent is composed of at least one of ethanol and propylene glycol;
the aromatic is at least one of orange essence, lemon essence and peppermint oil;
the carrier is defatted rice bran, more than 95% of the carrier passes through 80 meshes, and the water content is less than 5%;
the preparation method comprises the following steps:
step 1: dissolving a metal ion chelating agent in water, dissolving a sweetening agent and an aromatic agent in a solvent, adding a stabilizing agent, adding a metal ion chelating agent solution, and stirring to obtain a wetting agent A;
step 2: pouring the tylosin tartrate and the carrier into a groove-shaped mixer/stirring mixing device, adding half of the wetting agent A, covering the cover of the mixer, and mixing and stirring for 5 minutes;
and step 3: opening the cover of the mixer, adding the rest wetting agent A, closing the cover, and continuing stirring for 10 minutes;
and 4, step 4: opening the cover, observing the properties of the materials, holding the materials by hand to form a cluster, wherein the cluster is free from dust emission and uniform in whole, and if the cluster is not uniform, continuing to close the cover and stirring the mixture until the cluster is uniform to obtain a material B;
and 5: sieving the material B with a 40-mesh sieve for 2 times to obtain a material C;
step 6: and pouring the material C into a mixer, and stirring and mixing for 15 minutes to obtain the material C.
2. The preparation method of the antistatic tavermectin tartrate premix as claimed in claim 1, wherein the preparation method comprises the following steps: the sweetener is at least one of steviosin and sorbitol.
3. The preparation method of the antistatic tavermectin tartrate premix as claimed in claim 1, wherein the preparation method comprises the following steps: the stabilizer is composed of at least one of polyethylene glycol 200, polyethylene glycol 400 and polyethylene glycol 600.
4. The preparation method of the antistatic tavermectin tartrate premix as claimed in claim 1, wherein the preparation method comprises the following steps: the metal ion chelating agent is at least one of sodium tripolyphosphate, citric acid and ethylene diamine tetraacetic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711008783.8A CN107550867B (en) | 2017-10-25 | 2017-10-25 | Antistatic tavermectin tartrate premix and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711008783.8A CN107550867B (en) | 2017-10-25 | 2017-10-25 | Antistatic tavermectin tartrate premix and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107550867A CN107550867A (en) | 2018-01-09 |
| CN107550867B true CN107550867B (en) | 2020-11-10 |
Family
ID=60987181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711008783.8A Active CN107550867B (en) | 2017-10-25 | 2017-10-25 | Antistatic tavermectin tartrate premix and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107550867B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109010281B (en) * | 2018-10-10 | 2021-01-05 | 新昌县九信药业有限公司 | Tylosin tartrate premix and preparation method thereof |
| CN114469869B (en) * | 2022-01-14 | 2022-10-25 | 广州市和生堂动物药业有限公司 | Tylosin tartrate premix and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265711A (en) * | 2016-08-25 | 2017-01-04 | 浦城正大生化有限公司 | Tylosin phosphonate pre-mixing agent formula and preparation technology |
-
2017
- 2017-10-25 CN CN201711008783.8A patent/CN107550867B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106265711A (en) * | 2016-08-25 | 2017-01-04 | 浦城正大生化有限公司 | Tylosin phosphonate pre-mixing agent formula and preparation technology |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107550867A (en) | 2018-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105168143B (en) | A kind of Wymox and preparation method thereof | |
| CN104840426B (en) | A kind of amoxicillin soluble powder and its preparation method and application | |
| KR100255887B1 (en) | Laxative composition containing lactic acid bacterium | |
| CN107737106A (en) | Safe ten thousand rhzomorph sol particles of a kind of tartaric acid and preparation method thereof | |
| CN104397349A (en) | Feeding intestinal tract sustained-release type compound acidifier and preparation method thereof | |
| CN107550867B (en) | Antistatic tavermectin tartrate premix and preparation method thereof | |
| CN104546907A (en) | Enteric nano zinc oxide preparation and preparation method thereof | |
| Nikola et al. | The efficacy of two phytogenic feed additives in the control of swine dysentery | |
| CA2074385C (en) | Pleuromutilin complexes | |
| CN104839490A (en) | Compound premix feeds capable of improving maternal antibodies for sows and preparation method for compound premix feeds | |
| CN104996737A (en) | Feed acidifier coating preparation method | |
| CN104922073A (en) | Soluble florfenicol powder and preparation method thereof | |
| CN106721055A (en) | Feeding coating compound acidulant and preparation method thereof | |
| CN104800167B (en) | A kind of florfenicol soluble powder and preparation method thereof | |
| CN105053557A (en) | Preparation method of envelopes of phosphoric acid micropore acidulant granules | |
| CN105327334A (en) | Enteric coating pellets for treating piglet diarrhea and preparation method and application thereof | |
| CN107712353A (en) | A kind of feed addictive for preventing diarrhea of pigs and preparation method and application | |
| CN102698244B (en) | Drug composition used for preventing piglets from diarrhea and promoting piglets to grow | |
| CN104586777B (en) | Ceftiofur Hydrochloride powder-injection and preparation method and application | |
| CN103536604B (en) | A kind of wettable sulfamethoxazole trimethoprim powder and preparation method thereof | |
| CN104206915B (en) | Promote production method and the application thereof of the additive of piglet growth | |
| CN107998264A (en) | A kind of Chinese and Western medicine compound superfine powder for treating porcine respiratory disease and preparation method and application | |
| CN107308115A (en) | A kind of fumaric acid tiamulin soluble powder | |
| CN112641001A (en) | Anti-coating compound acidifier | |
| CN107929328A (en) | A kind of good ox toad particle manufacture craft of palatability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |